Phase 4 N=23 A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection
HIV Infections
Primary: Number of Participants With Serious Adverse Events (SAEs) — 6 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=882 Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Primary: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13 Pneumococcal Serotypes — 75; 83; 41; 49 titer
Phase 4 N=407 Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c (Glycosylated Haemoglobin) — -1.146; -0.529 percentage of glycosylated haemoglobin — p=<0.0001
Phase 4 N=1,199 13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India
Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) Within 1 Month After 13vPnC Vaccination — 0; 7; 0; 0 Percentage…
Phase 4 N=385 Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).
Hepatitis C, Chronic
Primary: Change From Baseline in Viral Load (log10 Reduction) at Week 12 — -3.26; -3.27 log (IU/mL) — p=0.978
Phase 4 N=63 Pregabalin In Adolescent Patients With Fibromyalgia
Fibromyalgia
Primary: Change From Baseline in Pain Numeric Rating Scale by Week — 6.7; -2.1; -1.8; -2.1 Number
Phase 4 N=13 Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients
Infection in Solid Organ Transplant Recipients
Primary: Area Under the Curve (AUC) — 21.0 mcg∙h/mL
Phase 4 N=40 Fibrinolysis Before Cardiopulmonary Bypass?
Pathologic Fibrinolysis
Primary: Di-Dimer Increase Before Cardiopulmonary Bypass — 317; 266; 317; 291 ng/mL
Phase 4 N=22 Transcranial Direct Current Stimulation, Treatment of Childhood Drug-Resistant Lennox-Gastaut Syndrome, A Pilot Study
Lennox-Gastaut Syndrome
Primary: Number of Seizure After Treatment by tDCS — 80.67; 93.43; 35.53; 93.14 seizures — p=<0.05
Phase 4 N=12 Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy
Pain
Primary: Maximum Plasma Concentration (Cmax) — 254 ng/mL
Phase 4 N=46 A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin A1c (HbA1c) From Baseline. — -0.9; -1.0 Percent (%) glycosylated haemoglobin
Phase 4 N=15 Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty
Pain
Primary: Maximum Plasma Concentration (Cmax) — 408 ng/mL
Phase 4 N=2,997 XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort
Chronic Total Occlusion of Coronary Artery · Vascular Disease · Myocardial Ischemia
Primary: Incidence of Composite of All Death, MI and Stroke (Defined as MACE)
Phase 4 N=171 Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease
Alzheimer's Disease
Primary: Overall Summary of Adverse Events (AEs) — 67.65; 47.06; 7.06; 0.59 Percentage of participants
Phase 4 N=32 Intranasal Oxytocin and Social Cognition, Implicit Preferences and Craving in Alcohol Drinkers
AOD Use, Abuse, and Dependence
Primary: Change in Craving on the Alcohol Urge Questionnaire (AUQ) After Administration of Oxytocin vs. Placebo During the 3-week Study. — 1.11; 0.69 units on a 7-pt Likert Scale